Pharmaceutical opinion : **Interaction between potent inducers and anti-HCV**

Patient : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DOB \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

After analyzing your patient's file, I noticed a problem with his medication.

**Sofosbuvir / Velpatasvir / Voxilaprevir (Vosevi)**   **and**

**Anti-TBs :** Rifampicin (Rifadin); Rifabutin(Mycobutin); Rifapentine (Priftin)

**Interaction mechanism :** Rifampicin is a potent CYP 3A4 and P-gp inducer. Rifabutin is a potent P-gp inducer a moderate CYP 3A4 inducer. Rifapentine is a CYP 3A4, 2C8/9 and P-gp inducer. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) is a substrate of CYP3A4, 2C8 and P-gp. This induction can therefore significantly decrease the plasma concentration of sofosbuvir, velpatasvir and/or voxilaprevir, thus leading to a loss of clinical efficacy.

***Sofosbuvir / Velpatasvir / Voxilaprevir (Vosevi) and anti-TBs***

Additional information:

Velpatasvir single dose of 100 mg + Rifampicin 600 mg QD : ↓82% and ↓71% of velpatasvir AUC and Cmax, respectively. Voxilaprevir single dose of 100 mg + Rifampicin 600 mg QD : ↓73% and ↓9% of voxilaprevir AUC and Cmax, respectively. According to the product monograph, concomitant use of Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) with potent or moderate P-gp/CYP 3A4 inducers such as rifampicin or rifabutin is contraindicated or not recommended.

Possible therapeutic options (Anti-TBs):

* Treat mycobacterium before treatment for hepatitis C.
* Re-evaluate the mycobacterial treatment and replace the anti-TB drug with an alternative that does not cause interactions with the anti-HCVs.

Dosage : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

* Other :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

**Follow-up :** Efficacy of anti-HCV and effectiveness and safety of the chosen alternative drug.

Do not hesitate to contact us for additional information.
In collaboration,

Pharmacist : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_​ Fax : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

As a prescription, date and sign:

Date : \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Signature and licence : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_